Wells Fargo’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-294
| Closed | -$1.72K | – | 7859 |
|
|
2022
Q4 | $1.72K | Buy |
294
+8
| +3% | +$42 | ﹤0.01% | 6046 |
|
|
2022
Q3 | $2K | Buy |
286
+109
| +62% | +$661 | ﹤0.01% | 6240 |
|
|
2022
Q2 | $1K | Buy |
177
+21
| +13% | +$83 | ﹤0.01% | 6697 |
|
|
2022
Q1 | $1K | Buy |
156
+1
| +0.6% | +$3 | ﹤0.01% | 6922 |
|
|
2021
Q4 | $0 | Sell |
155
-30,150
| -99% | -$100K | ﹤0.01% | 8119 |
|
|
2021
Q3 | $99K | Sell |
30,305
-143
| -0.5% | -$501 | ﹤0.01% | 5393 |
|
|
2021
Q2 | $128K | Sell |
30,448
-29,130
| -49% | -$123K | ﹤0.01% | 5204 |
|
|
2021
Q1 | $298K | Sell |
59,578
-12,822
| -18% | -$104K | ﹤0.01% | 4976 |
|
|
2020
Q4 | $915K | Buy |
72,400
+31,045
| +75% | +$354K | ﹤0.01% | 4093 |
|
|
2020
Q3 | $406K | Sell |
41,355
-28,915
| -41% | -$285K | ﹤0.01% | 4502 |
|
|
2020
Q2 | $700K | Buy |
70,270
+23,345
| +50% | +$224K | ﹤0.01% | 4086 |
|
|
2020
Q1 | $415K | Buy |
46,925
+20,296
| +76% | +$200K | ﹤0.01% | 4180 |
|
|
2019
Q4 | $246K | Sell |
26,629
-24,510
| -48% | -$174K | ﹤0.01% | 4829 |
|
|
2019
Q3 | $300K | Sell |
51,139
-1,405
| -3% | -$14.9K | ﹤0.01% | 4723 |
|
|
2019
Q2 | $630K | Buy |
52,544
+11,063
| +27% | +$119K | ﹤0.01% | 4228 |
|
|
2019
Q1 | $500K | Sell |
41,481
-45,850
| -53% | -$676K | ﹤0.01% | 4331 |
|
|
2018
Q4 | $1.1M | Buy |
87,331
+1,088
| +1% | +$15K | ﹤0.01% | 3774 |
|
|
2018
Q3 | $1.28M | Buy |
86,243
+13,304
| +18% | +$209K | ﹤0.01% | 3779 |
|
|
2018
Q2 | $1.23M | Buy |
72,939
+41,877
| +135% | +$813K | ﹤0.01% | 3847 |
|
|
2018
Q1 | $710K | Sell |
31,062
-66,808
| -68% | -$1.49M | ﹤0.01% | 4148 |
|
|
2017
Q4 | $2.53M | Buy |
97,870
+83,388
| +576% | +$1.68M | ﹤0.01% | 3183 |
|
|
2017
Q3 | $213K | Buy |
14,482
+1,228
| +9% | +$17.8K | ﹤0.01% | 4895 |
|
|
2017
Q2 | $185K | Sell |
13,254
-14,474
| -52% | -$213K | ﹤0.01% | 4836 |
|
|
2017
Q1 | $472K | Sell |
27,728
-11,498
| -29% | -$138K | ﹤0.01% | 4285 |
|
|
2016
Q4 | $403K | Buy |
39,226
+7,091
| +22% | +$64.8K | ﹤0.01% | 4349 |
|
|
2016
Q3 | $324K | Buy |
32,135
+136
| +0.4% | +$1.49K | ﹤0.01% | 4198 |
|
|
2016
Q2 | $359K | Sell |
31,999
-1,812
| -5% | -$23.1K | ﹤0.01% | 4092 |
|
|
2016
Q1 | $462K | Buy |
33,811
+25,216
| +293% | +$363K | ﹤0.01% | 3908 |
|
|
2015
Q4 | $163K | Buy |
8,595
+5,121
| +147% | +$111K | ﹤0.01% | 4589 |
|
|
2015
Q3 | $65K | Sell |
3,474
-5,196
| -60% | -$88.3K | ﹤0.01% | 5162 |
|
|
2015
Q2 | $129K | Sell |
8,670
-15,377
| -64% | -$234K | ﹤0.01% | 4878 |
|
|
2015
Q1 | $365K | Sell |
24,047
-9,826
| -29% | -$137K | ﹤0.01% | 4133 |
|
|
2014
Q4 | $451K | Buy |
33,873
+20,173
| +147% | +$260K | ﹤0.01% | 4008 |
|
|
2014
Q3 | $173K | Buy |
13,700
+750
| +6% | +$7.27K | ﹤0.01% | 4420 |
|
|
2014
Q2 | $131K | Buy |
12,950
+8,920
| +221% | +$86.1K | ﹤0.01% | 4572 |
|
|
2014
Q1 | $54K | Buy |
+4,030
| New | +$56.9K | ﹤0.01% | 4903 |
|
Wells Fargo's CNCE Position: Q1 2023 in Review
Wells Fargo sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 294 shares — an estimated $1.72K sold.
Wells Fargo first reported a position in CNCE in Q1 2014 and held it in 36 quarters. The position peaked at $2.53M in Q4 2017. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Wells Fargo reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Wells Fargo sold 294 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $1.72K.
- Wells Fargo first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 36 quarters.
- Wells Fargo's Concert Pharmaceuticals, Inc. position peaked at $2.53M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Wells Fargo's 13F filing for Q1 2023, filed 12 May 2023.